CRBP
CorbusDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
CRBP has multiple 2026 shots on goal: ASCO monotherapy data for CRB-701, potential mid-2026 registrational-study initiation after FDA alignment, and summer Phase 1b CRB-913 data, while company guidance suggests runway into 2028 [#PR-2026-04-07] [#PR-2026-04-14] [#PR-2026-03-09].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +45.7.
What can break
ASCO 2026 CRB-701 data may fail to show enough durability or subgroup strength to support the emerging registrational narrative [#PR-2026-04-07].
Momentum
18
Value
41
Sentiment
83
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.00 · Bull $18.00 · Bear $5.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $42.05
Why
Momentum18 · Δ7d -53.6
Value41 · Δ7d +0.1
Sentiment83 · Δ7d +45.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
18
34% active weight
Current posture
7d trendSoftening
Δ7d
-53.6
Δ21d
-53.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
83
33% active weight
Current posture
7d trendImproving
Δ7d
+45.7
Δ21d
+47.5
Why this grade
Composite grade D. Momentum 17.9 / Value 41.1 / Sentiment 82.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$143.59M
Beta
2.87
Shares Out
17.55M
P/E (TTM) · Derived
-2.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.68
Rev YoY
-
EPS YoY
-65.3%
Gross Margin
-
Op Margin
-
Net Debt
-$149.06M
Current Ratio
6.31
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology